Repurposing Licensed Drugs for Use Against Alzheimer's Disease

Area of Science:

• Pharmacology
• Neuroscience
• Drug Discovery

Background:

• Alzheimer's disease (AD) prevalence is rising with increased life expectancy.
• There is a critical need for effective AD treatments due to the lack of current options.
• Existing FDA-approved drugs offer a promising avenue for AD therapy development.

Purpose of the Study:

• To review evidence supporting the repurposing of FDA-approved drugs for Alzheimer's disease treatment.
• To encourage clinical investigation and off-label prescription of existing safe therapeutics for AD.

Main Methods:

• Review of drug mechanisms of action.
• Analysis of in vivo testing data.
• Examination of epidemiological data for approved compounds.

Main Results:

• Substantial evidence supports the repurposing of certain FDA-approved drugs for AD.
• Drug repurposing offers a more rapid and cost-effective drug development pathway.
• Existing therapeutics may improve the quality of life for AD patients.

Conclusions:

• Clinical testing of FDA-approved drugs for AD is warranted.
• Repurposing existing medications is a viable strategy to address the AD public health concern.
• Physicians may consider off-label prescription of safe, approved drugs for AD treatment.